Actelsar HCT

Maa: Euroopan unioni

Kieli: englanti

Lähde: EMA (European Medicines Agency)

Osta se nyt

Pakkausseloste Pakkausseloste (PIL)
24-10-2023
Valmisteyhteenveto Valmisteyhteenveto (SPC)
24-10-2023

Aktiivinen ainesosa:

Telmisartan, hydrochlorothiazide

Saatavilla:

Actavis Group hf

ATC-koodi:

C09DA07

INN (Kansainvälinen yleisnimi):

telmisartan, hydrochlorothiazide

Terapeuttinen ryhmä:

Agents acting on the renin-angiotensin system, Angiotensin II antagonists and diuretics

Terapeuttinen alue:

Essential Hypertension

Käyttöaiheet:

Treatment of essential hypertension.Actelsar HCT fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.Actelsar HCT fixed-dose combination (80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.Actelsar HCT fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Actelsar HCT 80 mg / 12.5 mg (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.

Tuoteyhteenveto:

Revision: 17

Valtuutuksen tilan:

Authorised

Valtuutus päivämäärä:

2013-03-13

Pakkausseloste

                                73
B. PACKAGE LEAFLET
74
PACKAGE LEAFLET: INFORMATION FOR THE USER
ACTELSAR HCT 40 MG/12.5 MG TABLETS
telmisartan/hydrochlorothiazide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Actelsar HCT is and what it is used for
2.
What you need to know before you take Actelsar HCT
3.
How to take Actelsar HCT
4.
Possible side effects
5.
How to store Actelsar HCT
6.
Contents of the pack and other information
1.
WHAT ACTELSAR HCT IS AND WHAT IT IS USED FOR
Actelsar HCT is a combination of two active substances, telmisartan
and hydrochlorothiazide in one
tablet. Both of these substances help to control high blood pressure.
-
Telmisartan belongs to a group of medicines called angiotensin II
receptor antagonists.
Angiotensin-II is a substance produced in your body which causes your
blood vessels to narrow
thus increasing your blood pressure. Telmisartan blocks the effect of
angiotensin II so that the
blood vessels relax, and your blood pressure is lowered.
-
Hydrochlorothiazide belongs to a group of medicines called thiazide
diuretics, which cause your
urine output to increase, leading to a lowering of your blood
pressure.
High blood pressure, if not treated, can damage blood vessels in
several organs, which could lead
sometimes to heart attack, heart or kidney failure, stroke, or
blindness. There are usually no symptoms
of high blood pressure before damage occurs. Thus it is important to
regularly measure blood pressure
to verify if it is within the normal range.
ACTELSAR HCT IS USED TO
treat high blood pr
                                
                                Lue koko asiakirja
                                
                            

Valmisteyhteenveto

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Actelsar HCT 40 mg/12.5 mg tablets
Actelsar HCT 80 mg/12.5 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Actelsar HCT 40 mg/12.5 mg tablets
Each tablet contains 40 mg telmisartan and 12.5 mg
hydrochlorothiazide.
Actelsar HCT 80 mg/12.5 mg tablets
Each tablet contains 80 mg telmisartan and 12.5 mg
hydrochlorothiazide.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet.
Actelsar HCT 40 mg/12.5 mg tablets
White or almost white, 6.55 x 13.6 mm oval-shaped and biconvex tablets
marked with “TH” on one
side.
Actelsar HCT 80 mg/12.5 mg tablets
White or almost white, 9.0 x 17.0 mm capsule-shaped tablets marked
with “TH 12.5” on both sides.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of essential hypertension.
Actelsar HCT fixed dose combination (40 mg telmisartan/12.5 mg
hydrochlorothiazide and
80 mg telmisartan/12.5 mg hydrochlorothiazide) is indicated in adults
whose blood pressure is not
adequately controlled on telmisartan alone.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_ _
Posology
Actelsar HCT should be taken in patients whose blood pressure is not
adequately controlled by
telmisartan alone. Individual dose titration with each of the two
components is recommended before
changing to the fixed dose combination. When clinically appropriate,
direct change from monotherapy
to the fixed combination may be considered.
-
Actelsar HCT 40 mg/12.5 mg may be administered once daily in patients
whose blood pressure
is not adequately controlled by telmisartan 40 mg
-
Actelsar HCT 80 mg/12.5 mg may be administered once daily in patients
whose blood pressure
is not adequately controlled by telmisartan 80 mg
Actelsar HCT is also available at the dose strength 80 mg/25 mg
3
_Special populations: _
_Patients with renal impairment _
Periodic monitoring of renal function is advised (see section 4.4).
_Patients with hepatic impairment _
In patients with mild to moderate hepatic impairment the po
                                
                                Lue koko asiakirja
                                
                            

Asiakirjat muilla kielillä

Pakkausseloste Pakkausseloste bulgaria 24-10-2023
Valmisteyhteenveto Valmisteyhteenveto bulgaria 24-10-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta bulgaria 26-03-2013
Pakkausseloste Pakkausseloste espanja 24-10-2023
Valmisteyhteenveto Valmisteyhteenveto espanja 24-10-2023
Pakkausseloste Pakkausseloste tšekki 24-10-2023
Valmisteyhteenveto Valmisteyhteenveto tšekki 24-10-2023
Pakkausseloste Pakkausseloste tanska 24-10-2023
Valmisteyhteenveto Valmisteyhteenveto tanska 24-10-2023
Pakkausseloste Pakkausseloste saksa 24-10-2023
Valmisteyhteenveto Valmisteyhteenveto saksa 24-10-2023
Pakkausseloste Pakkausseloste viro 24-10-2023
Valmisteyhteenveto Valmisteyhteenveto viro 24-10-2023
Pakkausseloste Pakkausseloste kreikka 24-10-2023
Valmisteyhteenveto Valmisteyhteenveto kreikka 24-10-2023
Pakkausseloste Pakkausseloste ranska 24-10-2023
Valmisteyhteenveto Valmisteyhteenveto ranska 24-10-2023
Pakkausseloste Pakkausseloste italia 24-10-2023
Valmisteyhteenveto Valmisteyhteenveto italia 24-10-2023
Pakkausseloste Pakkausseloste latvia 24-10-2023
Valmisteyhteenveto Valmisteyhteenveto latvia 24-10-2023
Pakkausseloste Pakkausseloste liettua 24-10-2023
Valmisteyhteenveto Valmisteyhteenveto liettua 24-10-2023
Pakkausseloste Pakkausseloste unkari 24-10-2023
Valmisteyhteenveto Valmisteyhteenveto unkari 24-10-2023
Pakkausseloste Pakkausseloste malta 24-10-2023
Valmisteyhteenveto Valmisteyhteenveto malta 24-10-2023
Pakkausseloste Pakkausseloste hollanti 24-10-2023
Valmisteyhteenveto Valmisteyhteenveto hollanti 24-10-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta hollanti 26-03-2013
Pakkausseloste Pakkausseloste puola 24-10-2023
Valmisteyhteenveto Valmisteyhteenveto puola 24-10-2023
Pakkausseloste Pakkausseloste portugali 24-10-2023
Valmisteyhteenveto Valmisteyhteenveto portugali 24-10-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta portugali 26-03-2013
Pakkausseloste Pakkausseloste romania 24-10-2023
Valmisteyhteenveto Valmisteyhteenveto romania 24-10-2023
Pakkausseloste Pakkausseloste slovakki 24-10-2023
Valmisteyhteenveto Valmisteyhteenveto slovakki 24-10-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta slovakki 26-03-2013
Pakkausseloste Pakkausseloste sloveeni 24-10-2023
Valmisteyhteenveto Valmisteyhteenveto sloveeni 24-10-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta sloveeni 26-03-2013
Pakkausseloste Pakkausseloste suomi 24-10-2023
Valmisteyhteenveto Valmisteyhteenveto suomi 24-10-2023
Pakkausseloste Pakkausseloste ruotsi 24-10-2023
Valmisteyhteenveto Valmisteyhteenveto ruotsi 24-10-2023
Pakkausseloste Pakkausseloste norja 24-10-2023
Valmisteyhteenveto Valmisteyhteenveto norja 24-10-2023
Pakkausseloste Pakkausseloste islanti 24-10-2023
Valmisteyhteenveto Valmisteyhteenveto islanti 24-10-2023
Pakkausseloste Pakkausseloste kroatia 24-10-2023
Valmisteyhteenveto Valmisteyhteenveto kroatia 24-10-2023

Etsi tähän tuotteeseen liittyviä ilmoituksia

Näytä asiakirjojen historia